Amphastar Pharma (AMPH) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Amphastar Pharmaceuticals (AMPH) PT Raised to $25 at Needham & Company
November 9, 2018 9:14 AM ESTNeedham & Company analyst Serge Belanger raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $25.00 (from $20.00) while maintaining a Buy rating.
Belanger commented, "AMPH delivered 3Q18 results that beat both top- and bottom-line Street consensus estimates, benefiting from a surprisising significant uptick in... More
